debio 1453p
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 18, 2025 (NCT07035769)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Enoyl-[acyl-carrier-protein]INHIBITOR
FABI inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07035769 | Phase 1 | Jun 18, 2025 | Debiopharm, Department of Health and Human Services, Wellcome Trust |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Debiopharm | For profit | 1 | 1 | 1 | 2025 |
| Department of Health and Human Services | Government | 1 | 0 | 1 | 2025 |
| Wellcome Trust | Academic/Hospital | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1